Omeros’ (OMER) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a $36.00 price target on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on OMER. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Omeros in a research note on Friday, June 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Friday, August 15th. Finally, Wall Street Zen downgraded Omeros from a “hold” rating to a “sell” rating in a research note on Friday, June 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.00.

Omeros Stock Performance

OMER stock opened at $4.17 on Wednesday. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The business’s 50-day moving average is $3.85 and its two-hundred day moving average is $5.31. The company has a market cap of $283.81 million, a price-to-earnings ratio of -1.98 and a beta of 2.37.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.02. The firm had revenue of $28.60 million during the quarter, compared to the consensus estimate of $0.31 million. Equities analysts predict that Omeros will post -3.09 earnings per share for the current year.

Institutional Trading of Omeros

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC raised its stake in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,972 shares during the period. GAMMA Investing LLC raised its stake in Omeros by 14,486.3% during the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 7,388 shares during the period. Harbour Investments Inc. raised its stake in Omeros by 51.9% during the 1st quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,149 shares during the period. Sowell Financial Services LLC bought a new stake in Omeros during the 1st quarter valued at approximately $88,000. Finally, Trexquant Investment LP bought a new stake in Omeros during the 1st quarter valued at approximately $88,000. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.